Adalimumab

Last updated

Adalimumab
Monoclonal antibody
Type Whole antibody
Source Human
Target TNF alpha
Clinical data
Trade names Humira
Other namesD2E7
Biosimilars adalimumab-aacf, [1] adalimumab-aaty, [2] adalimumab-adaz, [3] adalimumab-adbm, [4] adalimumab-afzb, [5] adalimumab-aqvh, [6] adalimumab-atto, [7] adalimumab-bwwd, [8] adalimumab-fkjp, [9] adalimumab-ryvk, [10] Abrilada, [11] Amgevita, [12] Amsparity, [13] Ardalicip, [14] Cadalimab, [15] Ciptunec, [14] Cyltezo, [16] Exemptia, [17] Hadlima, [8] Halimatoz, [18] Hefiya, [19] Hukyndra, [20] Hulio, [21] Hyrimoz, [22] Idacio, [23] Imraldi, [24] Kromeya, [25] Libmyris, [26] Mabura, Simlandi, [27] [10] Solymbic, [28] Trudexa, [29] Yuflyma, [2] [30] Yusimry [6]
AHFS/Drugs.com Monograph
MedlinePlus a603010
License data
Pregnancy
category
Routes of
administration 		Subcutaneous
Drug class TNF inhibitor
ATC code
Legal status
Legal status
Pharmacokinetic data
Bioavailability 64% (subcutaneous), 0% (by mouth)
Elimination half-life 10–20 days
Identifiers
CAS Number
DrugBank
ChemSpider
  • none
UNII
KEGG
ChEMBL
ECHA InfoCard 100.224.376 OOjs UI icon edit-ltr-progressive.svg
Chemical and physical data
Formula C6428H9912N1694O1987S46
Molar mass 144190.64 g·mol−1
 X mark.svgNYes check.svgY  (what is this?)    (verify)

Adalimumab, sold under the brand name Humira and others, is a disease-modifying antirheumatic drug and monoclonal antibody used to treat rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, ulcerative colitis, plaque psoriasis, hidradenitis suppurativa, and uveitis. [44] [45] [46] It is administered by subcutaneous injection (injection under the skin). [44] It works by inactivating tumor necrosis factor-alpha (TNFα). [44]

Contents

Common side effects include upper respiratory tract infections, pain at the site of injection, rash, and headache. [44] Other side effects may include serious infections, cancer, anaphylaxis, reactivation of hepatitis B, new onset or exacerbation of demyelinating diseases (such as multiple sclerosis), heart failure, liver failure, and aplastic anemia. [44] Use during pregnancy is not recommended, but some sources show use during breastfeeding may be safe. [31] [45]

Adalimumab was approved for medical use in the United States in 2002. [44] [47] It is on the World Health Organization's List of Essential Medicines. [48] It is available as a biosimilar medication. [49] In 2021, it was the 236th most commonly prescribed medication in the United States, with more than 1 million prescriptions. [50] [51]

Medical uses

In the US and the EU, adalimumab is indicated for the treatment of rheumatoid arthritis, juvenile idiopathic arthritis, psoriatic arthritis, ankylosing spondylitis, adult and pediatric Crohn's disease, ulcerative colitis, plaque psoriasis, hidradenitis suppurativa, and uveitis. [42] [52] [43] In the EU it is also indicated for chronic aggressive progressive pulmonary and bone sarcoidosis. [43]

Rheumatoid arthritis

Adalimumab has been shown to reduce the signs and symptoms of moderate to severe rheumatoid arthritis in adults. It may be used alone or in combination with disease-modifying antirheumatic drugs. [53] It has also been shown to have efficacy in moderate to severe polyarticular juvenile idiopathic arthritis in children four years and older, and is indicated for the treatment of that condition. In rheumatoid arthritis, it is indicated for use alone, or with methotrexate or similar medicines, in the United States since 2002. [54] It has a similar effectiveness as methotrexate and, in combination, nearly doubles the response rate of methotrexate alone. [55]

Juvenile idiopathic arthritis

Adalimumab has been shown to reduce the signs and symptoms of moderate to severe polyarticular juvenile idiopathic arthritis in children aged four years and older. [56] [57] [58]

Ankylosing spondylitis

Adalimumab has been shown to reduce the signs and symptoms of, and is approved for treatment for, ankylosing spondylitis in adults. [59]

Crohn's disease

Adalimumab has been shown to reduce the signs and symptoms of moderate to severe Crohn's disease. [49] [60] [61] It has been approved for that use in the UK since 2009. [62]

Ulcerative colitis

Adalimumab may be effective and well tolerated in ulcerative colitis. It was approved by the US Food and Drug Administration (FDA) for treatment of moderate to severe cases in adults. [63] [64]

Plaque psoriasis

Adalimumab has been shown to treat moderate to severe chronic plaque psoriasis in adults who have the condition in many areas of their body and who may benefit from taking injections or pills (systemic therapy) or phototherapy (treatment using ultraviolet light alone or with pills). [65] Adalimumab has been shown to be effective therapy when used either continuously or intermittently in patients with moderate to severe psoriasis. [66]

Hidradenitis suppurativa

Adalimumab was approved for hidradenitis suppurativa in 2015. [46] [67] [68]

Non-infectious uveitis

Adalimumab is indicated for the treatment of non-infectious uveitis (inflammation of the layer beneath the white of the eyeball). [42] [43]

Adverse effects

There is strong evidence that adalimumab increases risk of serious infections, such as tuberculosis, and it has also been reported to increase the risk of developing various cancers. [69] However, such an association may reflect an increased risk of developing malignancies inherent in the conditions being treated, and not with adalimumab itself. A systematic review published in 2018, found no increased cancer incidence rate in patients with chronic inflammatory disorders treated with adalimumab and other TNF inhibitors, as compared to those who were not, with a possible exception for non-melanoma skin cancer. [70]

There are rare reports of serious liver injury; rare reports of demyelinating central nervous system disorders; and rare reports of cardiac failure—the US Food and Drug Administration (FDA) issued a black box warning to doctors, which appears in the product labeling of adalimumab and other TNF-inhibiting drugs, instructing them to screen and monitor potential patients more carefully. [71] Anaphylaxis or other serious allergic reactions may also occur. Also drug induced lupus. [71]

Injection site reactions such as redness and pain are very common, and may occur in up to 80% of cases. [72]

History

Adalimumab was the first fully human monoclonal antibody approved by the US Food and Drug Administration (FDA). [73] It is derived from phage display. [73] [74]

Adalimumab was discovered as a result of a collaboration between BASF Bioresearch Corporation and Cambridge Antibody Technology, U.K., itself a collaboration of the government-funded Medical Research Council and three academics, which began in 1993. [73] [75]

Initially named D2E7, [76] it was then further manufactured at BASF Bioresearch Corporation, developed by BASF Knoll (BASF Pharma), and ultimately manufactured and marketed by Abbott Laboratories after Abbott's acquisition of BASF Pharma. On 1 January 2013, Abbott split into two companies, one retaining the Abbott name and the other named AbbVie. [77] As a result, AbbVie took over development and marketing of Humira. [78] [79] The brand name Humira stands for "human monoclonal antibody in rheumatoid arthritis", and was named by one of Abbott's employees, Richard J. Karwoski, who was also responsible for leading the effort to get Humira approved by the FDA.

It is the third TNF inhibitor, after infliximab and etanercept, to be approved in the United States. [73] It is constructed from a fully human monoclonal antibody, while infliximab is a mouse-human chimeric antibody and etanercept is a TNF receptor-IgG fusion protein.[ medical citation needed ]

The drug candidate was discovered initially using CAT's phage display technology and named D2E7. [76] The key components of the drug were found by guiding the selection of human antibodies from phage display repertoires to a single epitope of an antigen TNF alpha. [80] The ultimate clinical candidate, D2E7, was created and manufactured at BASF Bioresearch Corporation and taken through most of the drug development process by BASF Knoll, then further development, manufacturing and marketing by Abbott Laboratories, after Abbott acquired the pharmaceutical arm of BASF Knoll. [81]

Since 2008, adalimumab had been approved by the FDA for the treatment of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn's disease, moderate to severe chronic psoriasis and juvenile idiopathic arthritis. Although only approved for ulcerative colitis from late 2012, by the FDA in the disease's management, it had been used for several years in cases that have not responded to conventional treatment at standard dosing for Crohn's disease.[ citation needed ]

Adalimumab, sold under the brand name Humira, was approved for use in the United States in 2002. [47] [82]

Adalimumab, sold under the brand names Humira and Trudexa, was approved for use in the European Union in September 2003. [43] [83]

Research

Society and culture

Economics

The UK NHS in 2019 listed Humira, Amgevita, Hulio, Hyrimoz, Idacio, and Imraldi as biosimilars available on (almost free) prescription, to be updated in February 2022. [96] The annual cost of adalimumab, the costliest NHS drug, was expected to drop from £400m to £100m by 2021, the biggest saving in NHS history from a single drug negotiation. [97]

The best-selling drugs list published by Genetic Engineering & Biotechnology News, shows that Humira occupied the #1 position for 2015 (US$14.012 billion) and 2016 (US$16.078 billion) [98] From 2012 until the US patent expired in 2016, Humira led the list of top-selling pharmaceutical products, and in 2016, it had US$16 billion of global sales. [98] AbbVie reported that Humira achieved US$18.427 billion of sales in 2017. [99] Humira had the largest worldwide drug sales in 2019 and 2020 of US$19.7bn and US$20.4bn respectively. [100]

Biosimilars

From 2014, biosimilars were manufactured by several companies and sold at a lower price than before patent expiry. [95]

In 2014, Indian drugmaker Cadila Healthcare declared the launch of the first adalimumab biosimilar at a fifth of its US price. The generic was launched under the brand name Exemptia. [95] In 2016, Indian drugmaker Torrent Pharmaceuticals launched its biosimilar for adalimumab, called Adfrar. It is the second generic biosimilar of adalimumab. [101]

In September 2016, the FDA approved Amgen's biosimilar adalimumab-atto, sold under the brand name Amjevita. [7] [102] [103] [104] [105] [106]

In August 2017, the FDA approved German pharmaceutical company Boehringer Ingelheim's biosimilar, Cyltezo. [4] [102] [107] [108] [109] [110]

In 2017, the biosimilars Amgevita, [12] Solymbic, [28] Imraldi, [24] and Cyltezo [16] were approved for use in the European Union.

In 2018, the biosimilars Halimatoz, [18] Hefiya, [19] Hyrimoz, [22] and Hulio [21] were approved for use in the European Union.

Adalimumab biosimilars became available in the European Union in 2018, [111] allowing the National Health Service to make record-breaking cost-savings, [112] as this is the single most expensive drug used in NHS hospitals, costing more than £400 million a year for about 46,000 patients. [113]

In October 2018, adalimumab-adaz (Hyrimoz) was approved for use in the United States. [3] [102] [114]

In April 2019, Idacio [23] and Kromeya [25] were approved for use in the European Union.

In July 2019, adalimumab-bwwd (Hadlima), produced by Samsung Bioepsis, was approved for use in the US. [8] [102] [115] [116]

In November 2019, adalimumab-afzb (Abrilada) was approved in the United States. [5] [102] [117] [118] [119] It is the 25th biosimilar approved by the FDA. [120]

In February 2020, the biosimilar Amsparity was approved for use in the European Union. [13]

In June 2020, the biosimilar Idacio was approved for use in Australia. [36]

In July 2020, adalimumab-fkjp (Hulio) was approved for use in the United States. [9] [102] [121]

In August 2020, the biosimilar Cadalimab was launched in India by Cadila Pharmaceuticals. [15] [122]

Idacio was approved for medical use in Canada in October 2020. [123]

In November 2020, Amgevita, Hulio, and Hyrimoz were approved for medical use in Canada. [124] [125] [126]

Yuflyma was approved for medical use in the European Union in February 2021. [30]

In January 2021, Abrilada was approved for medical use in Canada. [11]

The biosimilars Libmyris and Hukyndra were approved for medical use in the European Union in November 2021. [26] [20]

In December 2021, adalimumab-aqvh (Yusimry) was approved for medical use in the United States. [6] [102] [127]

In December 2021, Yuflyma was approved for medical use in Canada. [128]

In January 2022, Simlandi was approved for medical use in Canada. [27] [129]

Adalimumab-aacf (Idacio) was approved for medical use in the United States in December 2022. [1] [102] [130]

In January 2023, the CHMP recommended that the high-concentration 100mg/ml Hyrimoz biosimilar be granted a pan-European marketing authorization for all indications covered by the reference medicine, including Crohn's disease, plaque psoriasis, ulcerative colitis, rheumatoid arthritis and uveitis. [131]

In January 2023, Simlandi was approved for medical use in Saudi Arabia. [132]

Adalimumab-aaty (Yuflyma) was approved for medical use in the United States in May 2023. [2] [102] [133] [134]

Starting in July 2023, when Humira's regulatory exclusivity lapsed, a number of biosimilars such as Hadlima, Hyrimoz, Cyltezo, and Celltrion were launched in the US. [102] [135] [136] [137]

In February 2024, adalimumab-ryvk (Simlandi) was approved for medical use in the United States. [102] [138] [10]

Royalty litigation

In March 2003, Cambridge Antibody Technology (CAT) stated its wish to "initiate discussions regarding the applicability of the royalty offset provisions for Humira" with Abbott Laboratories in the High Court of London. In November 2004, the trial began, and in December 2004, Justice Hugh Laddie ruled for CAT.

A short version of the full statement of the proceedings was released. [139] In it Justice Laddie remarked, "Abbott was in error when it made its first royalty payment to CAT calculated on the basis that only 2% of the Net Sales was due. It should have calculated on the basis of the full royalty of just over 5% and should have paid and continued to pay CAT accordingly." Justice Laddie went on to observe "...that the construction advanced by Abbott does violence to the language of the agreements, renders them obscure and makes little or no commercial sense. For this reason CAT wins the action." [140]

Abbott was required to pay CAT US$255 million, some of which was to be passed to its partners in development. [141] Of this sum, the Medical Research Council received US$191 million, and in addition, Abbott was asked to pay the MRC a further US$7.5 million over five years from 2006, providing that Humira remains on the market. The MRC also is to receive a further £5.1 million (sterling) in respect of past royalties. [142]

Patent litigation

In May 2009, Johnson & Johnson's Centocor unit, the maker of infliximab, won a ruling for $1.67 billion from Abbott Laboratories for patent infringement on the process for making Humira. [143] [144] However, in 2011, the judgment was overturned by the United States Court of Appeals for the Federal Circuit. [145] [146] In June 2020, a class action lawsuit filed by United Food and Commercial Workers Local 1500 (UFCW Local 1500) against AbbVie, alleging that the drug manufacturer used a patent thicket over 100 strong to maintain a monopoly on Adalimumab, was dismissed by the Northern District Court in Illinois. [147] The dismissal was affirmed by the Seventh Circuit Court of Appeals on 1 August 2022. [148]

AbbVie has extensively used the US patent system to delay competitors from entering the market, a process commonly known as "evergreening". [149] It filed 311 patents for Humira, of which 165 were granted. AbbVie sued Amgen, the manufacturer of Amjevita, in 2016 for violating 10 of its patents. Amgen agreed to delay sales until 2023, which allowed AbbVie to drive up prices of Humira. Between 2016 and 2023, the price of Humira went up by 60%, during which time AbbVie made $114 billion in revenue from Humira. [150]

Related Research Articles

<span class="mw-page-title-main">Infliximab</span> Biopharmaceutical drug for autoimmune disorders

Infliximab, a chimeric monoclonal antibody, sold under the brand name Remicade among others, is a medication used to treat a number of autoimmune diseases. This includes Crohn's disease, ulcerative colitis, rheumatoid arthritis, ankylosing spondylitis, psoriasis, psoriatic arthritis, and Behçet's disease. It is given by slow injection into a vein, typically at six- to eight-week intervals.

Etanercept, sold under the brand name Enbrel among others, is a biologic medical product that is used to treat autoimmune diseases by interfering with tumor necrosis factor (TNF), a soluble inflammatory cytokine, by acting as a TNF inhibitor. It has US Food and Drug Administration (FDA) approval to treat rheumatoid arthritis, juvenile idiopathic arthritis and psoriatic arthritis, plaque psoriasis and ankylosing spondylitis. Tumor necrosis factor alpha (TNFα) is the "master regulator" of the inflammatory (immune) response in many organ systems. Autoimmune diseases are caused by an overactive immune response. Etanercept has the potential to treat these diseases by inhibiting TNF-alpha.

<span class="mw-page-title-main">Rituximab</span> Biopharmaceutical drug

Rituximab, sold under the brand name Rituxan among others, is a monoclonal antibody medication used to treat certain autoimmune diseases and types of cancer. It is used for non-Hodgkin lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis, granulomatosis with polyangiitis, idiopathic thrombocytopenic purpura, pemphigus vulgaris, myasthenia gravis and Epstein–Barr virus-positive mucocutaneous ulcers. It is given by slow intravenous infusion. Biosimilars of Rituxan include Blitzima, Riabni, Ritemvia, Rituenza, Rixathon, Ruxience, and Truxima.

Bevacizumab, sold under the brand name Avastin among others, is a monoclonal antibody medication used to treat a number of types of cancers and a specific eye disease. For cancer, it is given by slow injection into a vein (intravenous) and used for colon cancer, lung cancer, ovarian cancer, glioblastoma, and renal-cell carcinoma. In many of these diseases it is used as a first-line therapy. For age-related macular degeneration it is given by injection into the eye (intravitreal).

<span class="mw-page-title-main">Biological therapy for inflammatory bowel disease</span>

Biological therapy, the use of medications called biopharmaceuticals or biologics that are tailored to specifically target an immune or genetic mediator of disease, plays a major role in the treatment of inflammatory bowel disease. Even for diseases of unknown cause, molecules that are involved in the disease process have been identified, and can be targeted for biological therapy. Many of these molecules, which are mainly cytokines, are directly involved in the immune system. Biological therapy has found a niche in the management of cancer, autoimmune diseases, and diseases of unknown cause that result in symptoms due to immune related mechanisms.

Ustekinumab, sold under the brand name Stelara among others, is a monoclonal antibody medication developed by Janssen Pharmaceuticals, for the treatment of Crohn's disease, ulcerative colitis, plaque psoriasis and psoriatic arthritis, targeting both IL-12 and IL-23.

<span class="mw-page-title-main">Golimumab</span> Pharmaceutical drug

Golimumab, sold under the brand name Simponi, is a human monoclonal antibody which is used as an immunosuppressive medication. Golimumab targets tumor necrosis factor alpha (TNF-alpha), a pro-inflammatory molecule and hence is a TNF inhibitor. Profound reduction in C-reactive protein (CRP) levels, interleukin (IL)-6, intercellaular adhesion molecules (ICAM)-1, matrix metalloproteinase (MMP)-3, and vascular endothelial growth factor (VEGF) demonstrates golimumab as an effective modulator of inflammatory markers and bone metabolism. Golimumab is given via subcutaneous injection.

Tocilizumab, sold under the brand name Actemra among others, is an immunosuppressive drug, used for the treatment of rheumatoid arthritis, systemic juvenile idiopathic arthritis, polyarticular juvenile idiopathic arthritis, giant cell arteritis, cytokine release syndrome, COVID‑19, and systemic sclerosis-associated interstitial lung disease (SSc-ILD). It is a humanized monoclonal antibody against the interleukin-6 receptor (IL-6R). Interleukin 6 (IL-6) is a cytokine that plays an important role in immune response and is implicated in the pathogenesis of many diseases, such as autoimmune diseases, multiple myeloma and prostate cancer. Tocilizumab was jointly developed by Osaka University and Chugai, and was licensed in 2003 by Hoffmann-La Roche.

<span class="mw-page-title-main">Canakinumab</span> Pharmaceutical drug

Canakinumab, sold under the brand name Ilaris, is a medication for the treatment of systemic juvenile idiopathic arthritis, active Still's disease, including adult-onset Still's disease, gout flares. It is a human monoclonal antibody targeted at interleukin-1 beta. It has no cross-reactivity with other members of the interleukin-1 family, including interleukin-1 alpha.

A biosimilar is a biologic medical product that is almost an identical copy of an original product that is manufactured by a different company. Biosimilars are officially approved versions of original "innovator" products and can be manufactured when the original product's patent expires. Reference to the innovator product is an integral component of the approval.

<span class="mw-page-title-main">Tofacitinib</span> Medication

Tofacitinib, sold under the brand Xeljanz among others, is a medication used to treat rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, polyarticular course juvenile idiopathic arthritis, and ulcerative colitis. It is a janus kinase (JAK) inhibitor, discovered and developed by the National Institutes of Health and Pfizer.

Ixekizumab, sold under the brand name Taltz, is an injectable medication for the treatment of autoimmune diseases. Chemically, it is a form of a humanized monoclonal antibody. The substance acts by binding interleukin 17A and neutralizing it, reducing inflammation.

<span class="mw-page-title-main">Secukinumab</span> Monoclonal antibody against IL-17

Secukinumab, sold under the brand name Cosentyx among others, is a human IgG1κ monoclonal antibody used for the treatment of psoriasis, ankylosing spondylitis, and psoriatic arthritis. It binds to the protein interleukin (IL)-17A and is marketed by Novartis.

Guselkumab, sold under the brand name Tremfya, is a monoclonal antibody against interleukin-23 used for the treatment of plaque psoriasis.

<span class="mw-page-title-main">Filgotinib</span> Chemical compound

Filgotinib, sold under the brand name Jyseleca, is a medication used for the treatment of rheumatoid arthritis (RA). It was developed by the Belgian-Dutch biotech company Galapagos NV.

Celltrion, Inc. is a biopharmaceutical company headquartered in Incheon, South Korea. Celltrion Healthcare conducts worldwide marketing, sales, and distribution of biological medicines developed by Celltrion. Celltrion's founder, Seo Jung-jin, is the richest person in South Korea.

Risankizumab, sold under the brand name Skyrizi, is a humanized monoclonal antibody used for the treatment of plaque psoriasis, psoriatic arthritis, and Crohn's disease. It is designed to target interleukin 23A (IL-23A). It is given by subcutaneous injection.

<span class="mw-page-title-main">Upadacitinib</span> Chemical compound (medication)

Upadacitinib, sold under the brand name Rinvoq, is a medication used for the treatment of rheumatoid arthritis, psoriatic arthritis, atopic dermatitis, ulcerative colitis, Crohn's disease, ankylosing spondylitis, and axial spondyloarthritis. Upadacitinib is a Janus kinase (JAK) inhibitor that works by blocking the action of enzymes called Janus kinases. These enzymes are involved in setting up processes that lead to inflammation, and blocking their effect brings inflammation in the joints under control.

Bimekizumab, sold under the brand name Bimzelx, is a humanized anti-IL17A, anti-IL-17F, and anti-IL17AF monoclonal antibody that is used to treat plaque psoriasis, psoriatic arthritis, axial spondyloarthritis, and ankylosing spondylitis.

References

  1. 1 2 3 "Idacio- adalimumab injection, solution". DailyMed. 22 March 2023. Archived from the original on 11 March 2024. Retrieved 11 March 2024.
  2. 1 2 3 4 "Yuflyma- adalimumab injection". DailyMed. 27 May 2023. Archived from the original on 26 June 2023. Retrieved 25 June 2023.
  3. 1 2 3 "Hyrimoz: FDA-Approved Drugs". U.S. Food and Drug Administration (FDA). 30 October 2018. Archived from the original on 7 December 2019. Retrieved 6 December 2019.PD-icon.svg This article incorporates text from this source, which is in the public domain .
  4. 1 2 "CYLTEZO- adalimumab-adbm kit". DailyMed. 12 July 2023. Archived from the original on 6 October 2023. Retrieved 6 October 2023.
  5. 1 2 3 "Abrilada- adalimumab-afzb kit; Abrilada- adalimumab-afzb injection, solution". DailyMed. 26 January 2024. Archived from the original on 30 April 2024. Retrieved 11 March 2024.
  6. 1 2 3 4 "Yusimry- adalimumab-aqvh injection, solution". DailyMed. 31 March 2023. Archived from the original on 6 October 2023. Retrieved 6 October 2023.
  7. 1 2 "Amjevita- adalimumab-atto injection". DailyMed. 11 April 2023. Archived from the original on 26 June 2023. Retrieved 25 June 2023.
  8. 1 2 3 4 "Hadlima- adalimumab-bwwd solution". DailyMed. 11 July 2023. Archived from the original on 6 October 2023. Retrieved 6 October 2023.
  9. 1 2 3 "Hulio- adalimumab kit". DailyMed. 9 August 2023. Archived from the original on 6 October 2023. Retrieved 6 October 2023.
  10. 1 2 3 "Simlandi- adalimumab-ryvk kit". DailyMed. 23 February 2024. Archived from the original on 2 April 2024. Retrieved 2 April 2024.
  11. 1 2 "Summary Basis of Decision (SBD) for Abrilada". Health Canada. 23 October 2014. Archived from the original on 29 May 2022. Retrieved 29 May 2022.
  12. 1 2 "Amgevita EPAR". European Medicines Agency (EMA). 17 September 2018. Archived from the original on 30 December 2019. Retrieved 18 February 2020.
  13. 1 2 "Amsparity EPAR". European Medicines Agency (EMA). 9 December 2019. Archived from the original on 18 February 2020. Retrieved 18 February 2020.
  14. 1 2 3 4 "Ciptunec/Ardalicip APMDS". Therapeutic Goods Administration (TGA). 27 September 2022. Retrieved 29 September 2022.
  15. 1 2 "Cadila Pharmaceuticals launches Cadalimab (Adalimumab biosimilar) for India". Cadila Pharmaceuticals (Press release). 28 August 2020. Archived from the original on 30 November 2022. Retrieved 11 February 2023.
  16. 1 2 "Cyltezo EPAR". European Medicines Agency (EMA). 17 September 2018. Archived from the original on 6 August 2020. Retrieved 18 February 2020.
  17. ↑ "First biosimilar Humira launches in India". 17 December 2014. Archived from the original on 25 March 2023. Retrieved 4 July 2023.
  18. 1 2 "Halimatoz EPAR". European Medicines Agency (EMA). 17 September 2018. Archived from the original on 30 December 2019. Retrieved 18 February 2020.
  19. 1 2 "Hefiya EPAR". European Medicines Agency (EMA). 17 September 2018. Archived from the original on 15 October 2019. Retrieved 18 February 2020.
  20. 1 2 "Hukyndra EPAR". European Medicines Agency (EMA). 14 September 2021. Archived from the original on 24 April 2022. Retrieved 23 April 2022.
  21. 1 2 "Hulio EPAR". European Medicines Agency (EMA). 17 September 2018. Archived from the original on 24 March 2020. Retrieved 18 February 2020.
  22. 1 2 "Hyrimoz EPAR". European Medicines Agency (EMA). 17 September 2018. Archived from the original on 16 November 2019. Retrieved 18 February 2020.
  23. 1 2 "Idacio EPAR". European Medicines Agency (EMA). 29 January 2019. Archived from the original on 30 December 2019. Retrieved 18 February 2020.
  24. 1 2 "Imraldi EPAR". European Medicines Agency (EMA). 17 September 2018. Archived from the original on 24 March 2020. Retrieved 18 February 2020.
  25. 1 2 "Kromeya EPAR". European Medicines Agency (EMA). 29 January 2019. Archived from the original on 30 December 2019. Retrieved 18 February 2020.
  26. 1 2 "Libmyris EPAR". European Medicines Agency (EMA). 14 September 2021. Archived from the original on 24 April 2022. Retrieved 23 April 2022.
  27. 1 2 "Summary Basis of Decision (SBD) for Simlandi". Health Canada. 23 October 2014. Archived from the original on 29 May 2022. Retrieved 29 May 2022.
  28. 1 2 "Solymbic EPAR". European Medicines Agency (EMA). 17 September 2018. Archived from the original on 25 June 2019. Retrieved 18 February 2020.
  29. ↑ "Trudexa EPAR". European Medicines Agency (EMA). 17 September 2018. Archived from the original on 18 February 2020. Retrieved 27 August 2021.
  30. 1 2 "Yuflyma EPAR". European Medicines Agency (EMA). 9 December 2020. Archived from the original on 28 August 2021. Retrieved 27 February 2021.
  31. 1 2 "Adalimumab Pregnancy and Breastfeeding Warnings". Drugs.com. Archived from the original on 17 April 2021. Retrieved 19 March 2019.
  32. 1 2 "Yuflyma APMDS". Therapeutic Goods Administration (TGA). 8 April 2022. Archived from the original on 24 April 2022. Retrieved 24 April 2022.
  33. ↑ AusPAR: Adalimumab. Therapeutic Goods Administration (TGA) (Report). September 2020. Archived from the original on 8 April 2023. Retrieved 6 October 2023.
  34. ↑ AusPAR: Adalimumab. Therapeutic Goods Administration (TGA) (Report). September 2020. Archived from the original on 6 October 2023. Retrieved 6 October 2023.
  35. ↑ AusPAR: Adalimumab. Therapeutic Goods Administration (TGA) (Report). September 2020. Archived from the original on 6 October 2023. Retrieved 6 October 2023.
  36. 1 2 https://www.tga.gov.au/resources/auspar/auspar-adalimumab-4 Archived 8 May 2023 at the Wayback Machine > "AusPAR: Adalimumab". Therapeutic Goods Administration (TGA). 23 September 2020. Archived from the original on 27 October 2020. Retrieved 23 September 2020.
  37. ↑ AusPAR: Adalimumab. Therapeutic Goods Administration (TGA) (Report). September 2020. Archived from the original on 6 October 2023. Retrieved 6 October 2023.
  38. ↑ AusPAR: Adalimumab. Therapeutic Goods Administration (TGA) (Report). September 2020. Archived from the original on 6 October 2023. Retrieved 6 October 2023.
  39. ↑ "Health product highlights 2021: Annexes of products approved in 2021". Health Canada . 3 August 2022. Archived from the original on 25 March 2024. Retrieved 25 March 2024.
  40. ↑ "Humira 40 mg solution for injection in pre-filled syringe - Summary of Product Characteristics (SmPC)". (emc). 27 November 2019. Archived from the original on 4 August 2020. Retrieved 12 August 2020.
  41. ↑ "FDA-sourced list of all drugs with black box warnings (Use Download Full Results and View Query links.)". nctr-crs.fda.gov. FDA . Retrieved 22 October 2023.
  42. 1 2 3 "Humira- adalimumab kit Humira- adalimumab injection, solution". DailyMed. Archived from the original on 21 June 2020. Retrieved 18 February 2020.
  43. 1 2 3 4 5 "Humira EPAR". European Medicines Agency (EMA). 17 September 2018. Archived from the original on 18 February 2020. Retrieved 18 February 2020. Text was copied from this source which is © European Medicines Agency. Reproduction is authorized provided the source is acknowledged.
  44. 1 2 3 4 5 6 "Adalimumab Monograph for Professionals". Drugs.com. American Society of Health-System Pharmacists. 14 May 2018. Archived from the original on 21 November 2020. Retrieved 18 March 2019.
  45. 1 2 British national formulary: BNF 76 (76 ed.). Pharmaceutical Press. 2018. p. 1074. ISBN   9780857113382.
  46. 1 2 3 Megan B (11 September 2015). "FDA Clears Adalimumab (Humira) for Hidradenitis Suppurativa". Medscape. Archived from the original on 21 January 2021. Retrieved 13 October 2017.
  47. 1 2 "Drug Approval Package: Humira (adalimumab)". U.S. Food and Drug Administration (FDA). 7 April 2017. Archived from the original on 18 February 2020. Retrieved 18 February 2020.
  48. ↑ World Health Organization (2023). The selection and use of essential medicines 2023: web annex A: World Health Organization model list of essential medicines: 23rd list (2023). Geneva: World Health Organization. hdl: 10665/371090 . WHO/MHP/HPS/EML/2023.02.
  49. 1 2 Peyrin-Biroulet L, Danese S, Cummings F, Atreya R, Greveson K, Pieper B, et al. (August 2019). "Anti-TNF biosimilars in Crohn's Disease: a patient-centric interdisciplinary approach". Expert Review of Gastroenterology & Hepatology. 13 (8): 731–738. doi: 10.1080/17474124.2019.1645595 . PMID   31322440.
  50. ↑ "The Top 300 of 2021". ClinCalc. Archived from the original on 15 January 2024. Retrieved 14 January 2024.
  51. ↑ "Adalimumab - Drug Usage Statistics". ClinCalc. Archived from the original on 8 July 2020. Retrieved 14 January 2024.
  52. ↑ "Imraldi- adalimumab injection, solution". DailyMed. 23 January 2018. Archived from the original on 21 September 2020. Retrieved 18 February 2020.
  53. ↑ Navarro-Sarabia F, Ariza-Ariza R, Hernandez-Cruz B, Villanueva I (July 2005). "Adalimumab for treating rheumatoid arthritis". The Cochrane Database of Systematic Reviews (3): CD005113. doi:10.1002/14651858.CD005113.pub2. PMID   16034967.
  54. ↑ Siegel JP (31 December 2002). "Product Approval Information - Licensing Action". U.S. Food and Drug Administration (FDA). Archived from the original on 24 October 2020. Retrieved 4 February 2014.PD-icon.svg This article incorporates text from this source, which is in the public domain .
  55. ↑ Welch B (15 December 2008). "Adalimumab (Humira) for the Treatment of Rheumatoid Arthritis". American Family Physician. 78 (12): 1406–1408. ISSN   0002-838X. Archived from the original on 24 November 2020. Retrieved 9 September 2019.
  56. ↑ Brunner HI, Nanda K, Toth M, Foeldvari I, Bohnsack J, Milojevic D, et al. (October 2020). "Safety and Effectiveness of Adalimumab in Patients With Polyarticular Course of Juvenile Idiopathic Arthritis: STRIVE Registry Seven-Year Interim Results". Arthritis Care & Research. 72 (10): 1420–1430. doi: 10.1002/acr.24044 . PMC   7589221 . PMID   31421019.
  57. ↑ Horneff G, Seyger MM, Arikan D, Kalabic J, Anderson JK, Lazar A, et al. (October 2018). "Safety of Adalimumab in Pediatric Patients with Polyarticular Juvenile Idiopathic Arthritis, Enthesitis-Related Arthritis, Psoriasis, and Crohn's Disease". The Journal of Pediatrics. 201: 166–175.e3. doi: 10.1016/j.jpeds.2018.05.042 . hdl: 2066/195625 . PMID   30054164.
  58. ↑ Correll CK, Bullock DR, Cafferty RM, Vehe RK (February 2018). "Safety of weekly adalimumab in the treatment of juvenile idiopathic arthritis and pediatric chronic uveitis". Clinical Rheumatology. 37 (2): 549–553. doi:10.1007/s10067-017-3890-4. PMID   29103180. S2CID   20099281.
  59. ↑ Maxwell LJ, Zochling J, Boonen A, Singh JA, Veras MM, Tanjong Ghogomu E, et al. (April 2015). "TNF-alpha inhibitors for ankylosing spondylitis" (PDF). The Cochrane Database of Systematic Reviews. 4 (4): CD005468. doi:10.1002/14651858.CD005468.pub2. PMID   25887212. Archived (PDF) from the original on 30 April 2024. Retrieved 14 December 2019.
  60. ↑ Podolsky DK (August 2002). "Inflammatory bowel disease" (PDF). The New England Journal of Medicine. 347 (6): 417–429. doi:10.1056/NEJMra020831. PMID   12167685. Archived from the original on 14 March 2020. Retrieved 24 September 2019.{{cite journal}}: CS1 maint: unfit URL (link)
  61. ↑ Gearry RB, Frampton C, Inns S, Poppelwell D, Rademaker M, Suppiah R (October 2019). "VITALITY: impact of adalimumab on health and disability outcomes in patients with Crohn's disease, rheumatoid arthritis, or psoriasis treated in clinical practice in New Zealand". Current Medical Research and Opinion. 35 (10): 1837–1846. doi:10.1080/03007995.2019.1634952. PMID   31233347. S2CID   195354397.
  62. ↑ Morey S (17 September 2009). "UK – Summary of NICE Approvals in September 2009". Archived from the original on 20 September 2018. Retrieved 4 February 2014.
  63. ↑ "FDA approves Humira to treat ulcerative colitis" (Press release). U.S. Food and Drug Administration (FDA). 28 September 2012. Archived from the original on 30 September 2012.PD-icon.svg This article incorporates text from this source, which is in the public domain .
  64. ↑ "Abbott's Humira (adalimumab) Receives U.S. FDA Approval for the Treatment of Adult Patients with Moderate to Severe Ulcerative Colitis". Abbott (Press release). 28 September 2012. Archived from the original on 19 November 2019. Retrieved 18 November 2019.
  65. ↑ Croom KF, McCormack PL (2009). "Adalimumab: in plaque psoriasis". American Journal of Clinical Dermatology. 10 (1): 43–50. doi:10.2165/0128071-200910010-00008. PMID   19170412.
  66. ↑ Menter A, Tyring SK, Gordon K, Kimball AB, Leonardi CL, Langley RG, et al. (January 2008). "Adalimumab therapy for moderate to severe psoriasis: A randomized, controlled phase III trial". Journal of the American Academy of Dermatology. 58 (1): 106–115. doi:10.1016/j.jaad.2007.09.010. PMID   17936411.
  67. ↑ Gulliver W, Zouboulis CC, Prens E, Jemec GB, Tzellos T (September 2016). "Evidence-based approach to the treatment of hidradenitis suppurativa/acne inversa, based on the European guidelines for hidradenitis suppurativa". Reviews in Endocrine & Metabolic Disorders. 17 (3): 343–351. doi:10.1007/s11154-016-9328-5. PMC   5156664 . PMID   26831295.
  68. ↑ Maarouf M, Clark AK, Lee DE, Shi VY (August 2018). "Targeted treatments for hidradenitis suppurativa: a review of the current literature and ongoing clinical trials". The Journal of Dermatological Treatment. 29 (5): 441–449. doi:10.1080/09546634.2017.1395806. PMID   29098911. S2CID   39246564.
  69. ↑ Hochman D, Wolff B (November 2006). "Risk of serious infections and malignancies with anti-TNF antibody therapy in rheumatoid arthritis". JAMA. 296 (18): 2203, author reply 2203-2203, author reply 2204. doi:10.1001/jama.296.18.2203-a. PMID   17090763.
  70. ↑ Chen Y, Friedman M, Liu G, Deodhar A, Chu CQ (January 2018). "Do tumor necrosis factor inhibitors increase cancer risk in patients with chronic immune-mediated inflammatory disorders?". Cytokine. 101: 78–88. doi:10.1016/j.cyto.2016.09.013. PMID   27688201. S2CID   20837188.
  71. 1 2 "Humira Medication Guide" (PDF). October 2018. Archived (PDF) from the original on 13 November 2008. Retrieved 9 September 2019.
  72. ↑ Yoshida T, Otaki Y, Katsuyama N, Seki M, Kubota J (November 2019). "New adalimumab formulation associated with less injection site pain and improved motivation for treatment". Modern Rheumatology. 29 (6): 949–953. doi:10.1080/14397595.2018.1520426. PMID   30183438. S2CID   52160836.
  73. 1 2 3 4 Frenzel A, Schirrmann T, Hust M (October 2016). "Phage display-derived human antibodies in clinical development and therapy". mAbs. 8 (7): 1177–1194. doi: 10.1080/19420862.2016.1212149 . PMC   5058633 . PMID   27416017.
  74. ↑ Brekke OH, Sandlie I (January 2003). "Therapeutic antibodies for human diseases at the dawn of the twenty-first century". Nature Reviews. Drug Discovery. 2 (1): 52–62. doi:10.1038/nrd984. PMID   12509759. S2CID   3181573.
  75. ↑ McCafferty J (2010). "The long and winding road to antibody therapeutics". mAbs. 2 (5): 459–460. doi:10.4161/mabs.2.5.13088. PMC   2958567 . PMID   20978369.
  76. 1 2 3 Kempeni J (November 1999). "Preliminary results of early clinical trials with the fully human anti-TNFalpha monoclonal antibody D2E7". Annals of the Rheumatic Diseases. 58 (Suppl 1): I70–I72. doi:10.1136/ard.58.2008.i70. PMC   1766582 . PMID   10577977.
  77. 1 2 "Abbott Completes Separation Of Research-Based Pharmaceuticals Business" (Press release). Abbott Laboratories. Archived from the original on 8 August 2020. Retrieved 9 September 2019.
  78. 1 2 Turner S (5 September 2018). "Humira: the highs and lows of the world's most successful drug". Pharmaceutical Technology. Archived from the original on 9 September 2019. Retrieved 9 September 2019.
  79. ↑ Japsen B (26 February 2019). "Why Abbvie May Have A Tough Time Defending Humira's Price Before Congress". Forbes . Archived from the original on 27 February 2019. Retrieved 9 September 2019.
  80. ↑ Jespers LS, Roberts A, Mahler SM, Winter G, Hoogenboom HR (September 1994). "Guiding the selection of human antibodies from phage display repertoires to a single epitope of an antigen". Bio/Technology. 12 (9): 899–903. doi:10.1038/nbt0994-899. PMID   7521646. S2CID   6096492.
  81. ↑ "BASF to focus more strongly on innovative chemistry, a highly efficient Verbund and a global presence" (Press release). Archived from the original on 12 February 2013. Retrieved 9 December 2012.
  82. ↑ "Humira: FDA-Approved Drugs". U.S. Food and Drug Administration (FDA). Archived from the original on 18 February 2020. Retrieved 18 February 2020.
  83. ↑ "Trudexa EPAR". European Medicines Agency (EMA). 17 September 2018. Archived from the original on 18 February 2020. Retrieved 18 February 2020.
  84. ↑ "Abbott Laboratories' Investigational Fully Human Anti-Tnf Therapy, D2E7 (Adalimumab), Shows Promise In Reducing The Signs And Symptoms Of Rheumatoid Arthritis" (Press release). 12 November 2001. Archived from the original on 4 December 2019. Retrieved 9 September 2019.
  85. 1 2 3 4 5 6 "Abbott 2006 Annual Report" (PDF). Abbott. Archived from the original on 13 January 2008. Retrieved 27 July 2009.
  86. ↑ Rau R (November 2002). "Adalimumab (a fully human anti-tumour necrosis factor alpha monoclonal antibody) in the treatment of active rheumatoid arthritis: the initial results of five trials". Annals of the Rheumatic Diseases. 61 (Suppl 2): ii70–ii73. doi:10.1136/ard.61.suppl_2.ii70. PMC   1766697 . PMID   12379628.
  87. ↑ "Eisai Submits New Drug Application for Rheumatoid Arthritis Drug Adalimumab (D2E7) in Japan". thefreelibrary.com. Archived from the original on 13 October 2012. Retrieved 27 July 2009.
  88. ↑ "Abbott 2007 Annual Report" (PDF). Abbott. Archived from the original on 3 May 2009. Retrieved 27 July 2009.
  89. ↑ "Abbott Opens New Biotechnology Manufacturing Facility In Puerto Rico" (Press release). Abbott. 10 April 2007. Archived from the original on 30 May 2009. Retrieved 27 July 2009.
  90. ↑ "Abbott's Humira (adalimumab) Receives FDA Approval For Moderate to Severe Chronic Plaque Psoriasis" (Press release). Abbott Laboratories. 18 January 2008. Archived from the original on 7 August 2020. Retrieved 9 September 2019.
  91. ↑ "Five-Year Data Demonstrate Initial Use Of Abbott's Humira (Adalimumab) Plus Methotrexate May Prevent Further Joint Damage In Early Rheumatoid Arthritis Patients" (Press release). Abbott. Archived from the original on 22 March 2010. Retrieved 27 July 2009.
  92. ↑ Papagoras C, Voulgari PV, Drosos AA (2009). "Long-term use of adalimumab in the treatment of rheumatic diseases". Open Access Rheumatology: Research and Reviews. 1: 51–68. doi: 10.2147/oarrr.s4297 . PMC   5074727 . PMID   27789981.
  93. ↑ "Treating psoriasis to prevent heart attacks and strokes". ScienceDaily. Archived from the original on 20 September 2018. Retrieved 9 March 2018.
  94. ↑ "Humira Lifts AbbVie 2.8% in Q2". Discovery and Development. Associated Press. 25 July 2014. Archived from the original on 27 July 2014. Retrieved 27 July 2014.
  95. 1 2 3 "India's Cadila launches first cheaper copy of world's top-selling drug". Reuters. 9 December 2014. Archived from the original on 27 March 2019. Retrieved 19 March 2019.
  96. ↑ "Adalimumab (Humira) and its biosimilars: medicine used for joint pain and inflammation". NHS (UK). 18 February 2019. Archived from the original on 3 January 2022. Retrieved 3 January 2022.
  97. ↑ "NHS set to save record £300 million on the NHS's highest drug spend". NHS England. 26 November 2018. Archived from the original on 3 January 2022. Retrieved 3 January 2022.
  98. 1 2 Philippidis A (6 March 2017). "The Top 15 Best-Selling Drugs of 2016". Genengnews.com. Archived from the original on 8 March 2018. Retrieved 8 March 2018.
  99. ↑ "AbbVie Reports Full-Year and Fourth-Quarter 2017 Financial Results". AbbVie (Press release). Archived from the original on 12 April 2018. Retrieved 8 March 2018.
  100. ↑ Urquhart L (April 2021). "Top companies and drugs by sales in 2020". Nature Reviews. Drug Discovery. 20 (4): 253. doi:10.1038/d41573-021-00050-6. PMID   33727694. S2CID   232262026.
  101. ↑ "Torrent launches world's second biosimilar of generic auto-immune drug". Business Standard . 11 January 2016. Archived from the original on 26 February 2016. Retrieved 1 March 2016.
  102. 1 2 3 4 5 6 7 8 9 10 11 "Biosimilar Drug Information". U.S. Food and Drug Administration (FDA). 27 December 2021. Archived from the original on 28 August 2021. Retrieved 27 December 2021.
  103. ↑ "Amjevita- adalimumab-atto injection". DailyMed. 11 April 2023. Archived from the original on 26 June 2023. Retrieved 25 June 2023.
  104. ↑ "Drug Approval Package: Amjevita (adalimumab-atto)". U.S. Food and Drug Administration (FDA). 9 November 2016. Archived from the original on 4 October 2020. Retrieved 11 February 2020.
  105. ↑ "FDA approves Amjevita, a biosimilar to Humira" (Press release). U.S. Food and Drug Administration (FDA). 23 September 2016. Archived from the original on 19 November 2019. Retrieved 18 November 2019.PD-icon.svg This article incorporates text from this source, which is in the public domain .
  106. ↑ "Amjevita: FDA-Approved Drugs". U.S. Food and Drug Administration (FDA). Archived from the original on 18 February 2020. Retrieved 18 February 2020.
  107. ↑ "Drug Approval Package: Cyltezo (adalimumab-adbm)". U.S. Food and Drug Administration (FDA). 27 September 2018. Archived from the original on 4 October 2020. Retrieved 11 February 2020.
  108. ↑ "FDA Approves Cyltezo, the First Interchangeable Biosimilar to Humira". U.S. Food and Drug Administration. 18 October 2021. Archived from the original on 21 October 2021. Retrieved 11 February 2023.
  109. ↑ "Cyltezo: FDA-Approved Drugs". U.S. Food and Drug Administration (FDA). Archived from the original on 18 February 2020. Retrieved 18 February 2020.
  110. ↑ "Boehringer Ingelheim Pharmaceuticals, Inc. receives FDA approval for Cyltezo (adalimumab-adbm), a biosimilar to Humira, for the treatment of multiple chronic inflammatory diseases" (Press release). Boehringer Ingelheim Pharmaceuticals. 29 August 2017. Archived from the original on 24 July 2019. Retrieved 19 March 2019.
  111. ↑ Hargreaves B (16 October 2018). "First wave of Humira biosimilars enters EU market". BioPharma-Reporter. Archived from the original on 15 August 2020. Retrieved 26 November 2018.
  112. ↑ Heal A (26 November 2018). "NHS replaces highest-spend drug with £300m cheaper alternative". The Guardian . Archived from the original on 26 November 2018. Retrieved 26 November 2018.
  113. ↑ Dent E (18 October 2018). "Most expensive NHS drug comes off patent". Pharmaceutical Journal. Archived from the original on 18 May 2021. Retrieved 29 November 2018.
  114. ↑ "Drug Approval Package: Hyrimoz". U.S. Food and Drug Administration (FDA). 21 March 2019. Archived from the original on 18 December 2019. Retrieved 11 February 2020.
  115. ↑ "Hadlima: FDA-Approved Drugs". U.S. Food and Drug Administration (FDA). Archived from the original on 19 October 2020. Retrieved 8 November 2019.PD-icon.svg This article incorporates text from this source, which is in the public domain .
  116. ↑ "Drug Approval Package: Hadlima". U.S. Food and Drug Administration (FDA). 5 September 2019. Archived from the original on 18 December 2019. Retrieved 11 February 2020.
  117. ↑ "Abrilada- adalimumab-afzb kit; Abrilada- adalimumab-afzb solution". DailyMed. 26 January 2024. Archived from the original on 30 April 2024. Retrieved 11 March 2024.
  118. ↑ "Abrilada: FDA-Approved Drugs". U.S. Food and Drug Administration (FDA). 15 November 2019. Archived from the original on 7 December 2019. Retrieved 6 December 2019.
  119. ↑ "Drug Approval Package: Abrilada". U.S. Food and Drug Administration (FDA). 28 January 2020. Archived from the original on 4 October 2020. Retrieved 11 February 2020.
  120. ↑ "Statement from Sarah Yim, M.D., acting director of the Office of Therapeutic Biologics and Biosimilars in the FDA's Center for Drug Evaluation and Research, on FDA's continued progress facilitating competition in the biologic marketplace with approval of 25th biosimilar product". U.S. Food and Drug Administration (FDA). 15 November 2019. Archived from the original on 19 November 2019. Retrieved 18 November 2019.PD-icon.svg This article incorporates text from this source, which is in the public domain .
  121. ↑ "Drug Approval Package: Hulio". U.S. Food and Drug Administration (FDA). 2 October 2020. Archived from the original on 6 November 2021. Retrieved 27 December 2021.
  122. ↑ "Cadila Pharma launches Cadalimab (adalimumab biosimilar) for India". Express Pharma. 29 August 2020. Archived from the original on 10 June 2022. Retrieved 7 September 2020.
  123. ↑ "Summary Basis of Decision (SBD) for Idacio". Health Canada. 23 October 2014. Archived from the original on 30 May 2022. Retrieved 29 May 2022.
  124. ↑ "Summary Basis of Decision (SBD) for Amgevita". Health Canada. 23 October 2014. Archived from the original on 30 May 2022. Retrieved 29 May 2022.
  125. ↑ "Summary Basis of Decision (SBD) for Hulio". Health Canada. 23 October 2014. Archived from the original on 29 May 2022. Retrieved 29 May 2022.
  126. ↑ "Summary Basis of Decision (SBD) for Hyrimoz". Health Canada. 23 October 2014. Archived from the original on 30 May 2022. Retrieved 29 May 2022.
  127. ↑ "Coherus Announces U.S. FDA Approval of Yusimry (adalimumab-aqvh)". Coherus BioSciences (Press release). 20 December 2021. Archived from the original on 28 December 2021. Retrieved 27 December 2021– via GlobeNewswire.
  128. ↑ "Summary Basis of Decision (SBD) for Yuflyma". Health Canada. 23 October 2014. Archived from the original on 29 May 2022. Retrieved 29 May 2022.
  129. ↑ "JAMP and Alvotech Announce Canadian Approval of Simlandi, a High-Concentration Biosimilar to Humira, Providing Access to Previously Unavailable Versions in Canada" (Press release). Alvotech. 10 January 2022. Archived from the original on 26 February 2024. Retrieved 26 February 2024– via Business Wire.
  130. ↑ "Drug Approval Package: Idacio". U.S. Food and Drug Administration (FDA). 9 February 2023. Archived from the original on 10 February 2023. Retrieved 9 February 2023.
  131. ↑ "Sandoz's high concentration Hyrimoz formulation recommended for use in EU". PMLive. 30 January 2023. Archived from the original on 31 January 2023. Retrieved 31 January 2023.
  132. ↑ "Alvotech and Bioventure Announce Approval of AVT02 (adalimumab) as Simlandi in Saudi Arabia". Alvotech. 24 January 2023. Archived from the original on 26 February 2024. Retrieved 26 February 2024.
  133. ↑ "Celltrion USA Announces U.S. FDA Approval of Yuflyma (adalimumab-aaty), a High-Concentration and Citrate-Free Formulation of Humira (adalimumab) Biosimilar" (Press release). Celltrion. 24 May 2023. Archived from the original on 25 May 2023. Retrieved 28 May 2023– via Business Wire.
  134. ↑ "Drug Approval Package: Yuflyma injection". U.S. Food and Drug Administration (FDA). 11 August 2023. Archived from the original on 25 August 2023. Retrieved 11 March 2024.
  135. ↑ "So it begins: next Humira biosimilars launch in US". pharmaphorum. Archived from the original on 5 July 2023. Retrieved 4 July 2023.
  136. ↑ Wingrove P (30 June 2023). "Analysis: New Humira rivals likely to hit US market with small discounts in July". Reuters. Archived from the original on 30 June 2023. Retrieved 4 July 2023.
  137. ↑ Wingrove P (1 July 2023). "Organon, Samsung Bioepis launch copycat for arthritis drug Humira at 85% discount". Reuters. Archived from the original on 1 July 2023. Retrieved 4 July 2023.
  138. ↑ "Alvotech and Teva Announce U.S. Approval of Simlandi (adalimumab-ryvk) injection, the first interchangeable high-concentration, citrate-free biosimilar to Humira" (Press release). Alvotech. 24 February 2024. Archived from the original on 26 February 2024. Retrieved 26 February 2024– via GlobeNewswire.
  139. ↑ "Cambridge Antibody Technology prevails in High Court proceedings regarding Humira". www.cambridgenetwork.co.uk. Cambridge Network. 20 December 2004. Archived from the original on 9 January 2021. Retrieved 5 January 2021.
  140. ↑ "Biotech firm wins royalty fight". BBC News Online. 20 December 2004. Archived from the original on 27 August 2021. Retrieved 23 April 2010.
  141. ↑ Murray-West R (27 October 2005). "Drug maker CAT surges after royalty settlement". The Telegraph . London. Archived from the original on 20 September 2018. Retrieved 23 April 2010.
  142. ↑ "Multi-Million Dollar Deal To Benefit Medical Research" (PDF) (Press release). Medical Research Council. Archived from the original (PDF) on 27 June 2007. Retrieved 20 July 2009.
  143. ↑ Centocor Ortho Biotech, Inc. v. Abbott Lab'ys, 669 F. Supp. 2d 756 (E.D. Tex. 2009) Archived 22 March 2022 at the Wayback Machine , rev'd, 636 F.3d 1341 (Fed. Cir. 2011).
  144. ↑ Pierson R, Spicer J (30 June 2009). "Jury returns $1.67 billion drug verdict against Abbott". Reuters. Archived from the original on 2 March 2021. Retrieved 9 September 2019.
  145. ↑ "Centocor Ortho Biotech v. Abbott Laboratories, 636 F. 3d 1341". United States Court of Appeals for the Federal Circuit. 23 February 2011. Archived from the original on 27 August 2021. Retrieved 9 September 2019– via Google Scholar.
  146. ↑ Decker S (23 February 2011). "Abbott Wins Reversal of J&J's $1.67 Billion Patent Victory". Bloomberg Businessweek . Archived from the original on 6 May 2011.
  147. ↑ Silbersher Z (10 June 2020). "Why was the Humira "patent thicket" antitrust case against AbbVie dismissed?". Markman Advisors. Archived from the original on 20 September 2020. Retrieved 6 October 2020.
  148. ↑ Mayor and City of Baltimore, et al. v. AbbVIE Inc., et al. Archived 3 August 2022 at the Wayback Machine , 7th Circuit Court of Appeals (decided 1 August 2022).
  149. ↑ Hansen K, Kolinsky MA (17 February 2020). "Humira: How far can drug makers go to protect their branded market?". The National Law Review . Archived from the original on 21 January 2022. Retrieved 28 January 2023.
  150. ↑ Rebecca R (28 January 2023). "How a Drug Company Made $114 Billion by Gaming the US Patent System". The New York Times . Archived from the original on 28 January 2023. Retrieved 28 January 2023.
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.